Naglaa H. Shoukry

Dr. Shoukry obtained her Pharmacy degree from Cairo University (1991) and Ph.D. in Immunology from McGill University (2000). Her postdoctoral research has established the essential and complementary roles of CD8 and CD4 T lymphocytes in resolution and protection from hepatitis C virus (HCV) infection. Since joining the Université de Montréal and CRCHUM in 2005, she has established a translational research program focused on studying immunity to HCV in a unique cohort of people who inject drugs in collaboration with Dr. Julie Bruneau. Recently, her research has expanded to studying immunological mechanisms of liver fibrosis progression and development of liver cancer. She has published over 77 articles in high impact journals related to HCV, HCV/HIV coinfection and liver immunology. Her research was/is funded by the Canadian Institutes of Health Research (CIHR), Fonds de recherche du Québec – Santé (FRQS), the Dana Foundation, the Canadian Foundation for Aids Research (CANFAR), the Canadian Liver Foundation (CLF) and the National Institutes of Health (NIH). She has served on various review committees on the national and international level including CIHR, FRQS, Canada Research Chairs, NIH and the Wellcome Trust. She is an Academic Editor for PLoS One, Viral Immunology and Frontiers in Immunology. In recognition, CIHR profiled her achievements on World Hepatitis Day in 2013 and 2017. In 2019, she was selected as Professor of the Year by the Department of Medicine, University of Montreal and was awarded the CLF 50th Anniversary Recognition Medal.

Since 2015 she has been the Director of the Canadian Network on Hepatitis C (CanHepC), federally funded network with over 100 investigators, trainees and knowledge users working towards establishing a pipeline from research to implementation and to improve the lives of Canadians living with hepatitis C and to work towards the eradication of HCV.